BioRestorative Therapies(BRTX)

Focus: BioRestorative Therapies is a public biotech focused on autologous stem cell therapy, currently in early clinical stage with one Phase 2 program for lumbar disc disease. The company operates at micro-cap scale with minimal revenue ($401K in FY 2025) and is heavily R&D-focused.

Cell Therapy Gene Therapy

Profile data last refreshed 14h ago · AI intelligence enriched 14h ago

Funding Stage

PUBLIC

Open Jobs

About BioRestorative Therapies

AI assessmentNot Hiring

No open roles listed right now. Follow BioRestorative Therapies to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$401K

Pipeline & Clinical Trials

BRTX-100

Lumbar Disc Disease

PHASE_2

Clinical Trials (1)

NCT04042844A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Phase 2

Help build intelligence for BioRestorative Therapies

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in autologous stem cell therapy, an emerging modality with significant commercial potential if BRTX-100 advances
Recent leadership additions (VP of Biocosmeceuticals, June 2026) signal expansion phase and new career pathways
Public company status provides equity transparency and potential liquidity absent in private biotech

Watch Out For

Extreme financial stress: $548K cash position (FY 2025) against $7M annual R&D burn and $9M net loss; runway likely <1 year at current burn
Minimal pipeline depth: only one Phase 2 program and zero active hiring (0 open roles) indicate organizational constraints and restructuring risk
Negligible revenue ($401K) and early-stage clinical assets create execution risk; no near-term value inflection catalysts

Generated by Claude from BioRestorative Therapies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.